La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Edap TMS a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Edap TMS..

Edap TMS (NASDAQ:EDAP) Azioni, Catena delle Opzioni

Edap TMS

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Edap TMS SA

WIIM

EDAP

Edap TMS shares are trading lower after Jefferies downgraded the stock from Buy to Hold and cut its price target from $8 to $2.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays analyst Manav Patnaik upgraded the rating for ADT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADT#NYSE">ADT</a>) from Underweight to Equal-Weight and raised the price target from $7 to $9. ADT shares closed at $8.08 on Thursday. <a href="https://www.benzinga.com/quote/ADT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt analyst Mike Genovese upgraded Coherent Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) from Neutral to Buy and lowered the price target from $115 to $85. Coherent shares closed at $53.91 on Thursday. <a href="https://www.benzinga.com/quote/COHR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst James Hardiman upgraded BRP Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) from Sell to Neutral and raised the price target from $27 to $37. BRP shares closed at $35.38 on Thursday. <a href="https://www.benzinga.com/quote/DOOO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Ben Gerlinger upgraded Flagstar Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLG#NYSE">FLG</a>) from Neutral to Buy and raised the price target from $13.5 to $15. Flagstar Financial shares closed at $10.79 on Thursday. <a href="https://www.benzinga.com/quote/flg/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Patrick Cunningham upgraded Eastman Chemical Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) from Neutral to Buy and lowered the price target from $105 to $101. Eastman Chemical shares closed at $79.98 on Thursday.  <a href="https://www.benzinga.com/quote/emn/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ADT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="594" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04081750/image-46-1024x594.png" alt="" class="wp-image-857450" style="width:547px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04081750/image-46-1024x594.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04081750/image-46-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04081750/image-46-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04081750/image-46.png 1092w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44641655/guess-simulations-plus-and-3-stocks-to-watch-heading-into-friday">Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday</a> </li>
</ul>
Photo via Shutterstock

News

Upgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

COHR

DOOO

This Eastman Chemical Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays analyst Manav Patnaik downgraded the rating for UniFirst Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) from Equal-Weight to Underweight and lowered the price target from $180 to $152. UniFirst shares closed at $172.17 on Thursday. <a href="https://www.benzinga.com/quote/UNF/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Janney Montgomery Scott analyst Michael Gaugler downgraded Middlesex Water Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSEX#NASDAQ">MSEX</a>) from Buy to Neutral. Middlesex Water shares closed at $66.57 on Thursday. <a href="https://www.benzinga.com/quote/MSEX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Michael Sarcone downgraded the rating for EDAP TMS S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) from Buy to Hold and cut the price target from $8 to $2. Edap shares closed at $1.91 on Thursday. <a href="https://www.benzinga.com/quote/EDAP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Jeffrey Zekauskas downgraded Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) from Overweight to Neutral and lowered the price target from $40 to $31. Dow shares closed at $31.46 on Thursday. <a href="https://www.benzinga.com/quote/DOW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Manav Patnaik downgraded the rating for Equifax Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) from Overweight to Equal-Weight and lowered the price target from $325 to $260. Equifax shares closed at $231.80 on Thursday.  <a href="https://www.benzinga.com/quote/EFX/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying DOW stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="505" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04081227/image-45-1024x505.png" alt="" class="wp-image-857437" style="width:509px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04081227/image-45-1024x505.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04081227/image-45-300x148.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04081227/image-45-768x379.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04081227/image-45.png 1212w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44641655/guess-simulations-plus-and-3-stocks-to-watch-heading-into-friday">Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday</a> </li>
</ul>
Photo via Shutterstock

Downgrades

MSEX

This Dow Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Jefferies analyst Michael Sarcone downgrades Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) from Buy to Hold and lowers the price target from $8 to $2.

Price Target

Jefferies Downgrades Edap TMS to Hold, Lowers Price Target to $2

Piper Sandler analyst Jason Bednar maintains Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) with a Overweight and lowers the price target from $5 to $4.5.

Piper Sandler Maintains Overweight on Edap TMS, Lowers Price Target to $4.5

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) with a Buy and maintains $19 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Edap TMS, Maintains $19 Price Target

<h3>Gainers</h3>
<ul>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares moved upwards by 81.6% to $8.59 during Thursday's after-market session. The company's market cap stands at $14.1 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares rose 40.69% to $0.73. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock moved upwards by 34.78% to $0.6. The company's market cap stands at $14.9 million. </li>
<li>Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) shares rose 17.33% to $0.8. The company's market cap stands at $44.1 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) stock rose 8.44% to $0.43. The market value of their outstanding shares is at $26.7 million. </li>
<li>Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) stock moved upwards by 8.1% to $2.4. The company's market cap stands at $89.0 million. As per the press release, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares decreased by 23.5% to $0.04 during Thursday's after-market session. The company's market cap stands at $1.0 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock fell 16.45% to $1.27. The company's market cap stands at $7.4 million. The company's, Q4 earnings came out today. </li>
<li>Equillium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQ#NASDAQ">EQ</a>) stock decreased by 13.86% to $0.42. The company's market cap stands at $14.8 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock fell 11.54% to $0.07. The market value of their outstanding shares is at $9.7 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares decreased by 10.82% to $0.82. The market value of their outstanding shares is at $1.4 million. The company's, Q4 earnings came out 3 days ago. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock declined by 9.35% to $0.21. The market value of their outstanding shares is at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

GCTK

LGMK

OCEA

PASG

PRLD

PRTG

PSTV

RNAZ

SLRX

SNSE

12 Health Care Stocks Moving In Thursday's After-Market Session

EDAP TMS shares are trading higher after the company reported better-than-expected Q4 financial results.

<h3>Gainers</h3>
<ul>
<li>Soleno Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) shares increased by 38.8% to $67.98 during Thursday's pre-market session. The company's market cap stands at $2.9 billion. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares moved upwards by 23.05% to $0.1. The market value of their outstanding shares is at $14.4 million. </li>
<li>Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) shares increased by 20.48% to $2.47. The market value of their outstanding shares is at $91.6 million. As per the press release, Q4 earnings came out today. </li>
<li>XTL Biopharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTLB#NASDAQ">XTLB</a>) shares moved upwards by 16.36% to $1.28. The company's market cap stands at $6.9 million. </li>
<li>Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) stock rose 16.27% to $1.5. The market value of their outstanding shares is at $99.3 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock rose 15.94% to $0.12. The company's market cap stands at $1.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) stock decreased by 21.9% to $2.96 during Thursday's pre-market session. The market value of their outstanding shares is at $57.0 million. </li>
<li>Equillium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQ#NASDAQ">EQ</a>) shares declined by 20.85% to $0.6. The market value of their outstanding shares is at $21.2 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock fell 11.19% to $0.12. The market value of their outstanding shares is at $3.0 million. </li>
<li>HeartSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares fell 10.09% to $2.62. The market value of their outstanding shares is at $2.8 million. </li>
<li>Leap Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPTX#NASDAQ">LPTX</a>) shares declined by 10.04% to $0.41. The company's market cap stands at $15.6 million. The company's, Q4 earnings came out yesterday. </li>
<li>Anebulo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANEB#NASDAQ">ANEB</a>) stock decreased by 8.39% to $1.42. The company's market cap stands at $58.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANEB

HSCS

LPTX

ONCO

OSRH

PTPI

RGLS

SLNO

XTLB

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Health Care

General

On March 26, 2025, EDAP TMS' Focal One Robotic HIFU System Received Ce Mark Certification From GMED, EDAP's Notified Body, For Posterior Deep Endometriosis Infiltrating The Rectum And Surrounding Structures

Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.10) by 50 percent. This is a 64.29 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $20.32 million which beat the analyst consensus estimate of $19.23 million by 5.66 percent. This is a 3.59 percent increase over sales of $19.61 million the same period last year.

Earnings

Edap TMS Q4 2024 GAAP EPS €(0.05) Beats €(0.10) Estimate, Sales €20.32M Beat €19.23M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Tsakos Energy Navigation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) is projected to report quarterly earnings at $0.40 per share on revenue of $154.43 million. 
• Worksport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) is projected to report quarterly loss at $1.40 per share on revenue of $2.90 million. 
• PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) is projected to report earnings for its fourth quarter. 
• FitLife Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTLF#NASDAQ">FTLF</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $14.95 million. 
• ADC Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>) is expected to report quarterly loss at $0.35 per share on revenue of $19.67 million. 
• Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) is expected to report earnings for its fourth quarter. 
• Acumen Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABOS#NASDAQ">ABOS</a>) is expected to report earnings for its fourth quarter. 
• Bitfarms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BITF#NASDAQ">BITF</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $53.82 million. 
• Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $608.95 million. 
• BK Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BKTI#AMEX">BKTI</a>) is estimated to report quarterly earnings at $0.35 per share on revenue of $16.80 million. 
• Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $20.83 million. 
• TriSalus Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $8.24 million. 
• BIO-key Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $2.29 million. 
• Icecure Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) is expected to report quarterly loss at $0.07 per share on revenue of $1.07 million. 
• Jiayin Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) is likely to report earnings for its fourth quarter. 
• Ascentage Pharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPG#NASDAQ">AAPG</a>) is projected to report earnings for its fourth quarter. 
• Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONEK#NASDAQ">UONEK</a>) is estimated to report earnings for its fourth quarter. 
• Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONE#NASDAQ">UONE</a>) is projected to report earnings for its fourth quarter. 
• TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) is likely to report quarterly earnings at $2.91 per share on revenue of $14.79 billion. 
• Sachem Cap (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SACH#AMEX">SACH</a>) is projected to report quarterly loss at $0.46 per share on revenue of $14.49 million. 
• Ermenegildo Zegna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZGN#NYSE">ZGN</a>) is likely to report earnings for its Fiscal Year 2024. 
• Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) is projected to report earnings for its Fiscal Year 2024. 
<h3>Companies Reporting After The Bell</h3>
• Dolphin Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $13.52 million. 
• Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) is projected to report earnings for its fourth quarter. 
• Draganfly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) is projected to report quarterly loss at $0.66 per share on revenue of $1.45 million. 
• Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) is projected to report quarterly loss at $0.09 per share on revenue of $3.85 million. 
• SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) is likely to report earnings for its fourth quarter. 
• INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) is projected to report earnings for its fourth quarter. 
• TMC Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) is estimated to report earnings for its fourth quarter. 
• Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) is expected to report quarterly loss at $0.40 per share on revenue of $9.03 million. 
• IZEA Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IZEA#NASDAQ">IZEA</a>) is expected to report quarterly loss at $0.08 per share on revenue of $13.00 million. 
• Yxt.Com Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) is expected to report earnings for its fourth quarter. 
• TSS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSSI#NASDAQ">TSSI</a>) is expected to report earnings for its fourth quarter. 
• BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) is likely to report quarterly loss at $0.27 per share on revenue of $475 thousand. 
• Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) is likely to report quarterly loss at $0.67 per share on revenue of $12.31 million. 
• Faraday Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) is expected to report earnings for its fourth quarter. 
• 374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) is likely to report quarterly loss at $0.02 per share on revenue of $100 thousand. 
• Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) is estimated to report earnings for its fourth quarter. 
• Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) is projected to report quarterly loss at $0.95 per share on revenue of $920 thousand. 
• Unusual Machines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#AMEX">UMAC</a>) is likely to report earnings for its fourth quarter. 
• BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) is expected to report earnings for its fourth quarter. 
• Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) is projected to report quarterly loss at $0.51 per share on revenue of $1.19 million. 
• VirTra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $8.09 million. 
• Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $5.37 million. 
• Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) is likely to report quarterly loss at $0.31 per share on revenue of $6.20 million. 
• Beachbody Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BODI#NYSE">BODI</a>) is likely to report quarterly loss at $1.52 per share on revenue of $81.71 million. 
• Stardust Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) is expected to report earnings for its fourth quarter. 
• Valhi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $19.48 million. 
• Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $81.13 million. 
• Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) is projected to report quarterly loss at $0.05 per share on revenue of $12.80 million. 
• AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) is projected to report quarterly earnings at $0.96 per share on revenue of $679.95 million. 
• Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) is expected to report quarterly earnings at $1.28 per share on revenue of $383.94 million. 
• P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) is expected to report quarterly loss at $0.17 per share on revenue of $385.80 million. 
• Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) is likely to report quarterly loss at $0.34 per share on revenue of $375 thousand. 
• Argan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGX#NYSE">AGX</a>) is estimated to report quarterly earnings at $1.11 per share on revenue of $212.05 million. 
• HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $9.30 million. 
• Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) is expected to report quarterly earnings at $5.65 per share on revenue of $3.52 billion. 
• Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) is likely to report quarterly loss at $0.11 per share on revenue of $294 thousand. 
• KULR Tech Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $2.87 million. 
• Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) is expected to report earnings for its fourth quarter. 
• Sky Harbour Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKYH#NYSE">SKYH</a>) is expected to report quarterly loss at $0.06 per share on revenue of $4.15 million. 
• Better Choice Co (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BTTR#AMEX">BTTR</a>) is likely to report earnings for its fourth quarter. 
• Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) is likely to report earnings for its fourth quarter. 
• Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $155.25 million. 
• Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) is likely to report quarterly loss at $0.14 per share on revenue of $68.43 million. 
• Spectral AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDAI#NASDAQ">MDAI</a>) is expected to report quarterly loss at $0.14 per share on revenue of $6.83 million. 
• Barfresh Food Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRFH#NASDAQ">BRFH</a>) is expected to report quarterly loss at $0.01 per share on revenue of $4.17 million. 
• Abacus Global Management (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) is expected to report quarterly earnings at $0.14 per share on revenue of $30.18 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAPG

ABOS

ADCT

BCAB

BITF

BKTI

BKYI

The Beachbody Company, Inc. Class A Common Stock

BODI

BRFH

BRTX

BRZE

BTTR

BZAI

CLSD

CODX

DLPN

DPRO

DRCT

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

FORA

FTLF

GEVO

GOVX

ICCM

INMB

IPHA

IRIX

IZEA

JFIN

KULR

LTRN

LULU

LVLU

MDAI

NUTX

PDSB

PIII

PLSE

RLMD

SACH

SCWO

SDST

SKYH

SPRO

SSKN

TLSI

TSAT

TSSI

UMAC

UONE

UONEK

VTSI

WKSP

Earnings Scheduled For March 27, 2025

Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) is set to give its latest quarterly earnings report on Thursday, 2025-03-27. Here's what investors need to know before the announcement.
Analysts estimate that Edap TMS will report an earnings per share (EPS) of $-0.12. 
Edap TMS bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.03, which was followed by a 6.04% drop in the share price the next day.
Here's a look at Edap TMS's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.16</td>
<td>-0.14</td>
<td>-0.11</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.19</td>
<td>-0.18</td>
<td>-0.13</td>
<td>-0.15</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-6.0%</td>
<td>9.0%</td>
<td>-3.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1743004922_0.png" alt="eps graph" />
<h3>Tracking Edap TMS's Stock Performance</h3>
Shares of Edap TMS were trading at $2.18 as of March 25. Over the last 52-week period, shares are down 72.31%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/EDAP/earnings">To track all earnings releases for Edap TMS visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Edap TMS

Company Reports Preliminary Worldwide Record Fourth Quarter Sales of 11 Focal One Systems&nbsp;
Record U.S. Fourth Quarter Focal One System Sales
Record Number of U.S. Focal One Procedures, with Year-Over-Year Growth of 30%

EDAP Reported Preliminary Worldwide Q4 Sales of 11 Focal One Systems, US Q4 Focal One System Sales

EDAP TMS Announced That The First Patient Has Been Treated In Phase 1/2 PULS Trial Evaluating Proprietary High-Intensity Focused Ultrasound Technology For Pancreatic Tumors

EDAP TMS shares are trading higher after the company announced it published results from the HIFI study in the European Urology peer-reviewed journal.

<ul>
<li>HIFI Study is the largest (N = 3,328) prospective, comparative, multi-center clinical study ever conducted comparing prostate cancer treatments</li>
<li>Positive study results are expected to drive further adoption of Focal One as a first line treatment option for the management of localized prostate cancer</li>
<li>Study shows Focal One Robotic HIFU is non-inferior to surgery, meeting primary endpoint of non-inferiority for Salvage Treatment-free Survival (STFS) after High Intensity Focused Ultrasounds (HIFU) compared to Radical Prostatectomy (RP) at 30 months</li>
<li>Study shows that patients receiving HIFU had better outcomes with respect to urinary continence and erectile function compared to patients receiving RP</li>
</ul>

Biotech

EDAP TMS Publishes HIFI Study Results In European Urology

EDAP TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.15) by 26.67 percent. The company reported quarterly sales of $14.42 million which missed the analyst consensus estimate of $15.56 million by 7.32 percent. This is a 13.61 percent increase over sales of $12.69 million the same period last year.

Earnings Misses

EDAP TMS Q3 2024 GAAP EPS $(0.19) Misses $(0.15) Estimate, Sales $14.42M Miss $15.56M Estimate

Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) will release its quarterly earnings report on Thursday, 2024-11-07. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Edap TMS to report an earnings per share (EPS) of $-0.16.
The market awaits Edap TMS's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
The company's EPS missed by $0.04 in the last quarter, leading to a 9.03% increase in the share price on the following day.
Here's a look at Edap TMS's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.14</td>
<td>-0.11</td>
<td>-0.05</td>
<td>-0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.18</td>
<td>-0.13</td>
<td>-0.15</td>
<td>-0.11</td>
</tr>
<tr>
<td>Price Change %</td>
<td>9.0%</td>
<td>-3.0%</td>
<td>4.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730908933_0.png" alt="eps graph" />
<h3>Edap TMS Share Price Analysis</h3>
Shares of Edap TMS were trading at $2.76 as of November 05. Over the last 52-week period, shares are down 45.91%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/EDAP/earnings">To track all earnings releases for Edap TMS visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse of Edap TMS's Earnings Potential

EDAP TMS SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>), the global leader in robotic energy-based therapies, today announced that the first patients have been treated in a Phase I/II study evaluating the Company's proprietary Focal One&#xAE; robotic high-intensity focused ultrasound (HIFU) technology for the treatment of benign prostatic hyperplasia (BPH). &nbsp;
"We've been offering targeted HIFU ablation to prostate cancer patients for more than 15 years," said Harry Toledano, MD, Head of the Urology Department of Martigues Hospital in Martigues, France. "Based on this large experience and the follow-up of hundreds of prostate cancer patients with their functional outcomes, we believe that the HIFU energy precisely delivered by Focal One has the potential to improve BPH symptoms with minimal side effects allowing a quick return to normal activities for a significant number of patients. We are enthusiastic to co-lead the first phase of this important clinical trial with our colleagues from Edouard Herriot Hospital – Lyon University and are looking forward to offering a new option to our BPH patients."
"We are excited to initiate this important clinical study evaluating Focal One robotic HIFU for the treatment of BPH, a condition which impacts millions of men each year," said Ryan Rhodes, Chief Executive Officer of EDAP TMS. "While there are other treatment options available for treating BPH, there remains a significant need for much less invasive treatment approaches that can preserve and protect the integrity of the urethra and other critical structures. We believe Focal One is ideally positioned to deliver this type of treatment solution, and this clinical approach in addressing BPH represents a logical next step in expanding our technology beyond the application in prostate cancer. We also believe this study will serve as a foundation for initiating a BPH clinical study in the United States next year."
The Phase I/II study is a company-sponsored, prospective, multicenter clinical trial designed as a two-part study. Part 1 of the Phase I/II study will take place at two leading academic prostate treatment centers in France with a recognized expertise in the treatment of BPH as well as in the use of Focal One HIFU technology. Part 1 is designed to define the optimal treatment parameters to effectively treat BPH and its related symptoms with minimal side effects. Part 2 of the study will expand patient enrollment across a larger number of treatment centers in order to validate the safety and efficacy of the parameters as defined in Part 1 of the study.

EDAP TMS Begins Phase I/II Trial for Robotic HIFU Treatment of Enlarged Prostate

Management

Press Releases

Senti Bio Appoints Fran Schulz to Board of Directors

Landmark HIFI Study Publication Demonstrates Positive Outcomes with Focal One® Robotic HIFU Versus Surgery in the Management of Prostate Cancer

EDAP Announces First Pancreatic Cancer Patient Treated with Proprietary HIFU Technology

EDAP Appoints Joshua H. Levine to Board of Directors

EDAP Announces Preliminary Record Fourth Quarter Focal One® System Sales and Record U.S. Procedures

Cortechs.ai and EDAP Announce World's First OnQ™ Prostate-Assisted Focal One® Robotic HIFU Procedure at UCSF Prostate Cancer Center

EDAP Appoints Glen French to Board of Directors

EDAP to Announce Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025

EDAP Reports Record HIFU Fourth Quarter and Full-Year 2024 Results

EDAP Announces Significant Presence of Focal One® at the Upcoming 120th American Urological Association (AUA) Annual Meeting

Comments

Edap TMS

Edap TMS (EDAP) Opzioni

Edap TMS (NASDAQ:EDAP) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO